MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
22nd Century Group DIO Ratio 2011-2026 | XXII
Annual DIO Ratio 22nd Century Group
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.8 | 47.9 | 30.4 | 27.8 | 32 | 43.5 | 69.2 | 88.8 | 109 | 1.51 K | 1.11 K | 6.61 K | 592 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.61 K | 27.8 | 794 |
Quarterly DIO Ratio 22nd Century Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.5 | 80.6 | 72.3 | - | 73.6 | 65.5 | 78.3 | - | 352 | 242 | 198 | - | 54.2 | 46.2 | 34.6 | - | 30.4 | 25.6 | 30.9 | - | 26.7 | 29.8 | 29 | - | 31.9 | 35 | 37.9 | - | 45.5 | 41.1 | 47.8 | - | 61.5 | 73.7 | - | - | - | - | - | - | 83.7 | - | - | - | 616 | - | - | - | 6.24 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.24 K | 25.6 | 306 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GlaxoSmithKline plc
GSK
|
200 | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Amphastar Pharmaceuticals
AMPH
|
132 | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M | Britain |
 |
Galapagos NV
GLPG
|
0.915 | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
Ultragenyx Pharmaceutical
RARE
|
1.25 K | $ 24.45 | 4.49 % | $ 2.21 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
BioXcel Therapeutics
BTAI
|
227 | $ 1.84 | 1.66 % | $ 4.66 M | USA |
 |
Aytu BioScience
AYTU
|
209 | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | USA |
 |
Coherus BioSciences
CHRS
|
116 | $ 2.04 | 28.3 % | $ 192 M | USA |
 |
Biogen
BIIB
|
394 | $ 171.89 | -1.1 % | $ 25 B | USA |